November 30, 2025

Market Outlook and Forecast

Marburg Virus Disease (MVD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Marburg Virus Disease (MVD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Marburg Virus Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 26, 2025

Market Outlook and Forecast

Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Extensive-Stage SCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 23, 2025

Market Outlook and Forecast

Monoamine Oxidase Deficiency (MAOD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Monoamine Oxidase Deficiency (MAOD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Monoamine Oxidase Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 20, 2025

Market Outlook and Forecast

Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Extensive-Stage Small-Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 24, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Hypercholesterolemia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Hypercholesterolemia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

March 27, 2026

Market Outlook and Forecast

Autism Spectrum Disorder (ASD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Autism Spectrum Disorder (ASD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autism Spectrum Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 31, 2026

Market Outlook and Forecast

Essential Tremor (ET) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Essential Tremor (ET) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Essential Tremor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 28, 2026

Market Outlook and Forecast

Fabry Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Fabry Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fabry Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 20, 2026

Market Outlook and Forecast

Friedreich Ataxia (FA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Friedreich Ataxia (FA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Friedreich Ataxia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 29, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Cerebral Vasospasm (CVS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Cerebral Vasospasm (CVS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

March 23, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

March 21, 2026

Market Outlook and Forecast

Global Cisplatin-Induced Hearing Loss (CIHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Thelansis’s “Global Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cisplatin-Induced Hearing Loss treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

1 2 161